Single Ascending Dose and Multiple Ascending Dose Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-04

Study Completion Date

2026-06-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if drug MDI2517 is safe and to learn more about its drug effects in healthy participants. Healthy participants will take single or multiple doses of drug and the safety and drug levels will be measured.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SAD Evaluation of Safety, Tolerability, PK, and PD of MDI-2517 in Healthy Participants

NCT06453824

Safety and Tolerability

COMPLETED PHASE1

Single Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of BDM-2 in Healthy Male Subjects.

NCT03634085

Healthy

COMPLETED PHASE1

An Ascending Dose Study to Evaluate M281 Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)

NCT02828046

Healthy Volunteers

COMPLETED PHASE1

AZD8075 Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of AZD8075 in Healthy Male Volunteers

NCT00829127

Healthy

WITHDRAWN PHASE1

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males

NCT02484729

Safety Tolerability Pharmacokinetics +1 more

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The goal of this clinical trial is to learn if drug MDI2517 is safe and to learn more about its drug effects in healthy participants. Healthy participants will take single or multiple doses of drug and the safety and drug levels will be measured. Healthy participants will be monitored for adverse events, laboratory test changes, changes in vital signs, electrocardiogram and the plasma drug levels will be measured. The amount of the drug and its metabolites in urine and blood will be measured. Blood and urine will be used to evaluate the effects of MDI-2517.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Safety After Oral Intake

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SAD 1

SAD cohort 1 will receive a single oral dose of 2400 mg of MDI-2517 or matching placebo

Group Type ACTIVE_COMPARATOR

Placebo

Intervention Type OTHER

Matching Placebo

MDI-2517 2400mg

Intervention Type DRUG

MDI-2517 2400mg will be administered

SAD 2

SAD cohort 2 will receive a single oral dose up to 3600 mg of MDI-2517 or matching placebo.

Group Type ACTIVE_COMPARATOR

Placebo

Intervention Type OTHER

Matching Placebo

MDI-2517 3600mg

Intervention Type DRUG

MDI-2517 3600mg will be administered

MAD 1

MAD cohort 1 will receive a total daily dose of 800 mg of MDI-2517 or matching placebo administered either once daily (QD) or twice daily (BID).

Group Type ACTIVE_COMPARATOR

MDI-2517 800mg

Intervention Type DRUG

800mg MDI-2517 will be administered

Placebo

Intervention Type OTHER

Matching Placebo

MAD 2

MAD cohort 2 will receive a total daily dose of up to 1600 mg of MDI-2517 or matching placebo administered either QD or BID.

Group Type ACTIVE_COMPARATOR

Placebo

Intervention Type OTHER

Matching Placebo

MDI-2517 1600mg

Intervention Type DRUG

MDI-2517 1600mg will be adminstered

MAD 3

MAD cohort 3 will receive a total daily dose of up to 2400 mg of MDI-2517 or matching placebo administered either QD or BID.

Group Type ACTIVE_COMPARATOR

Placebo

Intervention Type OTHER

Matching Placebo

MDI-2517 2400mg

Intervention Type DRUG

MDI-2517 2400mg will be administered

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MDI-2517 800mg

800mg MDI-2517 will be administered

Intervention Type DRUG

Placebo

Matching Placebo

Intervention Type OTHER

MDI-2517 1600mg

MDI-2517 1600mg will be adminstered

Intervention Type DRUG

MDI-2517 2400mg

MDI-2517 2400mg will be administered

Intervention Type DRUG

MDI-2517 3600mg

MDI-2517 3600mg will be administered

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Capable to understand the study procedures and providing signed informed consent as described Section 8.2, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
2. Healthy male and female participants 18 to 55 years of age inclusive, at the time of signing the informed consent.
3. Body weight of a minimum 50 kg for men and 45 kg for women and body mass index (BMI) within the range of 18.5 to 32 kg/m2
4. Participants who are generally healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring.
5. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Female participants should be of nonchildbearing potential (postmenopausal i.e., spontaneous amenorrhea for at least 12 months prior to dosing with confirmatory follicle-stimulating hormone \[FSH\] \> 40 mIU/mL, or premenopausal and surgically sterilized), or of childbearing potential who agree to take highly effective contraceptive measures throughout the trial (see Section 11.15 for highly effective contraceptive guidance). Sexually active female participants of childbearing potential with non-sterile male partners, and sexually active non-surgically sterile male participants with female partners of childbearing potential will be required to use highly effective double contraceptive method. Women of childbearing potential and those with less than 24 weeks from menopause must undergo a urine pregnancy test at screening and result must be negative.
6. Ability to refrain from consumption of Seville oranges, grapefruit or grapefruit juice, pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices from 7 days before participants check into the clinical site until collection of the final PK sample for each participant.
7. Ability to abstain from ingesting caffeine- or xanthine-containing products (eg, coffee, black/green tea, cola drinks, and chocolate) or energy drinks for 48 hours before participants check into the clinical site until after collection of the final PK and/or PD sample.
8. Ability to abstain from alcohol for 24 hours before admission to the clinical site until after collection of the final PK and/or PD sample.
9. Ability to swallow multiple tablets within a 10 minute window.

Exclusion Criteria

1. Major medical illness or unstable medical condition within 6 months of screening that in the opinion of the investigator may interfere with the participant's ability to comply with study procedures and abide by study restrictions, or with the ability to interpret safety data that would prevent completion of study procedures or assessments.
2. Any clinically significant abnormal finding at Screening during the physical examination or a clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
3. Chronic or ongoing active infectious disease requiring systemic treatment including, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, and tuberculosis.
4. Any acute infections within 14 days of screening.
5. Live attenuated vaccines received within 1 month of screening. Other vaccines, including coronavirus 2019 (COVID-19) vaccine, within 14 days prior to Screening.
6. Participants known or suspected of not being able to comply with this study protocol (eg, due to alcoholism, drug dependency or psychological disorder)
7. Laboratory values as follows:

1. Any clinically significant lab abnormalities
2. AST or ALT; \> the upper limit of normal (ULN)
3. Total bilirubin \> 1.5 times ULN (isolated bilirubin \> 1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin is \< 35%)
4. Platelet counts \< 150 × 109/L or \> 450 × 109/L
5. Hemoglobin outside of normal limits
6. Coagulation tests (prothrombin time, partial thromboplastin time) outside of normal limits
8. Screening corrected QT interval (QTc) \> 450 milliseconds for males and \> 470 ms for females. The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF), machine read or manually overread.
9. Screening estimated glomerular filtration rate (eGFR) using 2021 CKD-EPI method \<90 mL/min/1.73m2
10. Positive serology test results for Hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen and antibody at screening. Positive evaluation for COVID-19 infection.
11. History of significant allergic reactions (eg, anaphylactic reaction, hypersensitivity, angioedema) to any drug.
12. Use of prescription or nonprescription drugs, including vitamins, herbal and dietary supplements within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication through the final study visit, unless in the opinion of the investigator and Medical Monitor the medication will not interfere with the study procedures or compromise participant safety with the exception of oral contraception or the occasional use of acetaminophen (up to 2 g daily). Use of monoamine oxidase inhibitors and St. John's Wort within 30 days of dosing.
13. Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs, eg, acetylsalicylic acid) or selective serotonin reuptake inhibitors within 7 days prior to screening through the final study visit.
14. Use of tobacco products or uses other nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, inhalers or vapes) from 3 months before screening until final follow-up visit. Use of cigarettes 3 months before screening until final visit.
15. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 7 units for women or 14 units for men of alcohol per week (1 unit = 340 mL of beer 5%, 140 mL of wine 12%, or 45 mL of distilled alcohol 40%) through the final study visit.
16. History of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine \[PCP\], crack, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to screening through the final study visit.
17. History of hypersensitivity to platelet concentrates or human plasma proteins.
18. Any type of known platelet function disorder.
19. Individuals with increased risk of thrombotic events (eg, history of pulmonary embolism or thrombosis).
20. Any blood product donation given or received within 3 weeks of screening or loss of 500 mL or more of whole blood within 8 weeks prior to dosing.
21. Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration. Previously received MDI-2517 study drug or placebo in this study.
22. Positive pregnancy test or lactating female participant

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes